<DOC>
	<DOCNO>NCT00098787</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin , irinotecan , leucovorin , fluorouracil , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth colorectal cancer block blood flow tumor . Giving bevacizumab together combination chemotherapy may better way block tumor growth . Studying amount enzyme find tumor may help doctor plan best treatment . PURPOSE : This randomized phase II trial study give bevacizumab , oxaliplatin , irinotecan give bevacizumab , oxaliplatin , leucovorin , fluorouracil treat patient metastatic recurrent colorectal cancer .</brief_summary>
	<brief_title>Bevacizumab Oxaliplatin Combined With Irinotecan Leucovorin Fluorouracil Treating Patients With Metastatic Recurrent Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare response rate ( complete partial ) , progression-free survival , overall survival patient previously untreated metastatic locally recurrent colorectal adenocarcinoma high v low thymidylate synthase ( TS ) expression treat fluorouracil , leucovorin calcium , oxaliplatin , bevacizumab irinotecan , oxaliplatin , bevacizumab . - Compare toxicity regimens patient . - Correlate gene expression response rate patient treat regimen . - Correlate gene expression toxicity regimens patient . - Correlate dihydropyrimidine dehydrogenase , thymidine phosphorylase , mammalian excision repair cross complementary protein expression antitumor response patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord thymidylate synthase ( TS ) expression level ( high v low indeterminate ) . Patients high TS expression randomize 1 2 treatment arm ( Arms A B ) . Patients low indeterminate TS expression assign Arm C. - Arm A : Patients receive bevacizumab IV 30-90 minute follow oxaliplatin IV 2 hour irinotecan IV 90 minute day 1 15 . - Arm B : Patients receive bevacizumab oxaliplatin arm A , leucovorin calcium IV 2 hour , fluorouracil IV 5 minute continuously 46 hour day 1 15 . - Arm C : Patients receive bevacizumab , oxaliplatin , leucovorin calcium , fluorouracil arm B . In arm , course repeat every 28 day absence unacceptable toxicity disease progression . Patients follow every 3 month 2 year every 6 month 2 year date study registration .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Formyltetrahydrofolates</mesh_term>
	<mesh_term>Tetrahydrofolates</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>INCLUSION : Metastatic locally recurrent colorectal adenocarcinoma Measurable disease At least 2 formalinfixed paraffin embed core needle biopsy OR fine needle aspirate contain minimum 3 cluster malignant cell fix tissue previous biopsy If tissue sample available patient must willing undergo biopsy metastatic site Age 18 Eastern Cooperative Oncology Group ( ECOG ) Performance status 02 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Prothrombin time ( PT ) /international normalize ratio ( INR ) ≤ 1.5 unless patient receive fulldose anticoagulant AND follow criterion meet : Inrange INR ( usually 2 3 ) AND stable dose warfarin low molecular weight heparin No active bleed pathological condition associate high risk bleed Partial thromboplastin time ( PTT ) &lt; 1.5 time upper limit normal ( ULN ) Alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) &lt; 3 time ULN Bilirubin ≤ 1.5 time ULN Creatinine ≤ 1.8 mg/dL Meets 1 follow criterion : Protein negative urine dipstick Urine protein/creatinine ratio &lt; 1.0 Less 2 g protein 24hour urine collection Patients history hypertension must meet following criterion : Blood pressure &lt; 150/90 mm Hg Stable regimen antihypertensive therapy More 28 day since prior major open surgery Negative pregnancy test Fertile patient must use effective contraception 3 month study participation Prior noncolorectal malignancy allow provide follow criterion meet : No current clinical evidence persistent recurrent disease No active therapy noncolorectal malignancy , include hormonal therapy EXCLUSION : Pregnant nursing Arterial thromboembolic event within past 6 month , include follow : Transient ischemic attack Cerebrovascular accident Unstable angina pectoris Myocardial infarction Symptomatic arrhythmia Symptomatic congestive heart failure Clinically significant peripheral artery disease New York Heart Association class III IV heart disease Serious nonhealing wound , ulcer , bone fracture within past 28 day Significant traumatic injury within past 28 day Neuropathy ≥ grade 2 Ongoing active infection Concurrent prophylactic filgrastim ( GCSF ) sargramostim ( GMCSF ) Prior chemotherapy metastatic disease . Adjuvant therapy complete least 12 month first evidence metastasis allow Cardiovascular , renal , hepatic , nonmalignant systemic disease would preclude study therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>